Lidoject (Lidocaine Hydrochloride)

• Lidoject, a topical local anesthetic, is used to provide surface anesthesia in several clinical situations.
• Minor skin procedures: provides localized numbness to facilitate biopsies, suturing or minor excisions.
• Superficial wound or irritation: relieves pain from cuts, abrasions or irritant contact.
• Mucous membranes: anesthetizes oral or nasal mucosa prior to minor interventions.

• Lidoject contains lidocaine hydrochloride, which reversibly blocks voltage‑gated sodium channels on neuronal membranes. By inhibiting sodium influx, it prevents depolarization and propagation of nerve impulses, resulting in a temporary loss of sensation in the applied area without affecting surrounding tissues.

Lidoject may cause local or systemic adverse reactions following topical application.

Common Side Effects

• Transient burning or stinging at the application site
• Mild erythema or redness
• Pruritus or itching
• Localized swelling
• Dryness of the skin or mucosa
• Temporary tingling sensation

Serious or Rare Side Effects

• Allergic contact dermatitis
• Systemic toxicity presenting as dizziness, tinnitus, or seizures
• Cardiac arrhythmia or conduction disturbances
• Severe local tissue necrosis
• Anaphylactic reaction
• Methemoglobinemia (rare)

• When using Lidoject, consider the following safety measures.
• Allergy assessment: avoid use in patients with known lidocaine hypersensitivity.
• Application area: limit to intact skin or mucosa; do not apply to large surface areas.
• Concurrent anesthetics: avoid combining with other topical anesthetics to prevent cumulative toxicity.
• Medical conditions: use cautiously in patients with cardiac conduction disorders or severe liver disease.
• Pregnancy and lactation: consult a healthcare professional before use.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lidoject can interact with other medications; monitor patients accordingly.

Major Interactions (Avoid)

• Other amide‑type local anesthetics: may increase systemic toxicity.
• Class I antiarrhythmic drugs (e.g., quinidine, procainamide): can potentiate cardiac effects.
• Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise lidocaine plasma levels.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may enhance lidocaine's bradycardic effect.
• Diuretics (e.g., furosemide): may affect plasma protein binding and increase free drug concentration.